Hao H, d'Alincourt-Salazar M, Kelley K M M, Shatnawi A, Mukherjee S, Shah Y M, Ratnam M
Department of Biochemistry and Cancer Biology, Medical University of Ohio, Toledo, OH 43614, USA.
Oncogene. 2007 Dec 13;26(57):7872-84. doi: 10.1038/sj.onc.1210592. Epub 2007 Jun 25.
Estradiol (E2) acts through the estrogen receptor (ER) to downregulate many genes, and tamoxifen (Tam) largely reverses this repression but the underlying mechanisms are unclear. Repression of the folate receptor (FR)-alpha P4 core promoter by ER is enhanced by E2 and reversed by Tam. This effect was unaffected by inhibition of new protein synthesis and required the E/F and the DNA-binding domains of ER without direct binding of ER to DNA. The repression by E2/ER was not specific for either Sp1 or TATA elements but was loosely selective for the initiator and flanking sequence. Insertion of a response element or a relatively strong Sp1 cluster to recruit ER upstream of the core promoters caused a switch to activation by E2/ER that was inhibited by Tam. In nuclear extracts, association of ER with a biotinylated core promoter fragment was promoted by E2 but Tam blocked this effect. Repression/de-repression of the P4 promoter and endogenous FR-alpha expression by E2/Tam required SMRT and/or NCoR. ER associated with the chromosomal P4 promoter and SMRT and NCoR associated with it in an ER-dependent manner; these associations were favored by E2 but disrupted by Tam, in the short term, without changes in ER expression. TAFII30 was required for optimal P4 promoter activity and for the repressive association of ER. E2 may thus maintain a low transcriptional status of genes by favoring direct TAFII30-dependent association of ER with the core promoter in a co-repressor complex containing SMRT and/or NCoR; this repression is overridden in target genes containing an upstream element that strongly recruits ER. In addition to suppressing the activation of classical E2 target genes, Tam may upregulate genes by passively dissociating the ER co-repressor complex.
雌二醇(E2)通过雌激素受体(ER)作用来下调许多基因,而他莫昔芬(Tam)在很大程度上可逆转这种抑制作用,但其潜在机制尚不清楚。E2可增强ER对叶酸受体(FR)-α P4核心启动子的抑制作用,而Tam可逆转这种抑制作用。这种效应不受新蛋白质合成抑制的影响,并且需要ER的E/F结构域和DNA结合结构域,而ER无需直接与DNA结合。E2/ER的抑制作用对Sp1或TATA元件均无特异性,但对起始子和侧翼序列具有一定的选择性。在核心启动子上游插入一个反应元件或一个相对较强的Sp1簇以募集ER,会导致E2/ER激活,而这种激活会被Tam抑制。在核提取物中,E2可促进ER与生物素化的核心启动子片段结合,但Tam可阻断这种效应。E2/Tam对P4启动子的抑制/去抑制作用以及对内源性FR-α表达的影响需要SMRT和/或NCoR。ER以ER依赖性方式与染色体P4启动子结合,SMRT和NCoR也与之结合;这些结合在短期内受E2促进,但被Tam破坏,而ER表达无变化。TAFII30是P4启动子最佳活性以及ER抑制性结合所必需的。因此,E2可能通过在含有SMRT和/或NCoR的共抑制复合物中促进ER与核心启动子直接进行TAFII30依赖性结合,从而维持基因的低转录状态;在含有能强烈募集ER的上游元件的靶基因中,这种抑制作用会被克服。除了抑制经典E2靶基因的激活外,Tam可能通过被动解离ER共抑制复合物来上调基因。